Standard Biotools (LAB) Capital Expenditures (2010 - 2026)

Standard Biotools (LAB) has 17 years of Capital Expenditures data on file, last reported at $319000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $319000.0, down 93.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.9 million (down 163.81% YoY), and the FY2025 annual result was $851000.0, down 53.09% from the prior year.
• Capital Expenditures grew to $319000.0 in Q1 2026 per LAB's latest filing, from -$7.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $5.1 million in Q1 2025 and troughed at -$7.0 million in Q4 2025.
• A 5-year average of $400529.4 and a median of $879000.0 in 2024 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 547.12% in 2025 and fell as far as 893.63% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $755000.0 in 2022, then tumbled by 464.64% to -$2.8 million in 2023, then soared by 131.93% to $879000.0 in 2024, then plunged by 893.63% to -$7.0 million in 2025, then surged by 104.57% to $319000.0 in 2026.
• Business Quant data shows LAB's Capital Expenditures at $319000.0 in Q1 2026, -$7.0 million in Q4 2025, and $886000.0 in Q3 2025.